References
- Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010;31:139–170.
- Carter Y, Sippel RS, Chen H, et al. Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management. Oncologist. 2014;19:34–43.
- Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616–635.
- Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:64–73.
- Sciacchitano S, Lavra L, Morgante A, et al. Galectin-3: one molecule for an alphabet of diseases, from A to Z. Int J Mol Sci. 2018;19:379.
- Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33:67–75.
- Song L, Tang JW, Owusu L, et al. Galectin-3 in cancer. Clin Chim Acta. 2014;431:185–191.
- Makki FM, Taylor SM, Shahnavaz A, et al. Serum biomarkers of papillary thyroid cancer. J Otolaryngol Head Neck Surg. 2013;42:16.
- Sadler GP, Clark OH, Van Heerden JA, et al. Thyroid and parathyroid. In: Schwartz SI, editor. Principles of surgery. 7th ed. New York: McGrawHill; 1999. p. 1661–1713.
- Pang J, Nguyen VT, Rhodes DH, et al. Relationship of galectin-3 with obesity, IL-6, and CRP in women. J Endocrinol Invest. 2016;39:1435–1443.
- Yoshii T, Inohara H, Takenaka Y, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Cancer. 2001;18:787–792.
- Bartolazzi A, Sciacchitano S, D’Alessandria C. Galectin-3: the impact on the clinical management of patients with thyroid nodules and future perspectives. Int J Mol Sci. 2018;19:445.
- Albi E, Krüger M, Hemmersbach R, et al. Impact of gravity on thyroid cells. Int J Mol Sci. 2017;18:972.
- Peter HJ, Burgi U, Gerber H. Pathogenesis of nontoxic diffuse and nodular goiter. In: Brawerman LE, Utiger RD, editors. The thyroid. 7th ed. New York: Lippincott-Raven; 1996. p. 890–908.
- Ingbar HS, Brauerman EL. Genetic factors in thyroid disease. In: Lewis E, Sidney H, editors. Werner’s the thyroid: fundamental and clinical text. New York: JB Lippincott; 1989. p. 113–135.
- Dhirapong A, Lleo A, Leung P, et al. The immunological potential of galectin-1 and -3. Autoimmun Rev. 2009;8:360–363.
- Panjwani N. Role of galectins in re-epithelialization of wounds. Ann Transl Med. 2014;2:89.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285:2486–2497.
- Dumont JE, Lamy F, Roger P, et al. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev. 1992;72:667–697.
- Milazzo G, La Rosa GL, Catalfamo R, et al. Effect of TSH in human thyroid cells: evidence for both mitogenic and antimitogenic effects. J Cell Biochem. 1992;49:231–238.
- McLachlan SM, Rapoport B. Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies? Thyroid. 2004;14:510–520.
- Phillips D, McLachlan S, Stephenson A, et al. Autosomal dominant transmission of autoantibodies to thyroglobulin and thyroid peroxidase. J Clin Endocrinol Metab. 1990;70:742–746.
- Lilley JS, Lomenick JP. Delayed diagnosis of hypothyroidism following excision of a thyroglossal duct cyst. J Pediatr. 2013;162:427–428.
- Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J. 2011;5:76–84.